Marksans Pharma announced that its wholly owned UK subsidiary, Relonchem, has received marketing authorization from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for its Metformin Hydrochloride oral solution.

Metformin Hydrochloride is a commonly prescribed treatment for type-2 diabetes, especially beneficial for patients who have difficulty swallowing tablets and require an oral liquid formulation.

This approval paves the way for Marksans Pharma to market and distribute the oral solution across the UK.